Endocrine complications of new anticancer therapies

Author:

Miner Michał1,Elbaum Michał1,Jawiarczyk-Przybyłowska Aleksandra1,Kubicka Eliza1

Affiliation:

1. Katedra i Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

Abstract

Studying and analyzing of complex molecular mechanisms and immunological processes of cancer enables oncology to introduce new cancer therapies. In the treatment of cancer, we successively increase the use of targeted therapies with tyrosine kinase inhibitors and mTOR inhibitors and immunotherapy using checkpoint inhibitors CTLA-4 (cytotoxic T-cell antigen-4) and PD-1/PD-L1 (programmed death receptor 1/programmed death ligand 1). New anticancer drugs gradually replace conventional chemotherapy and have already found application in the treatment of many cancers, including thyroid cancer, hepatocellular carcinoma, non-small cell lung cancer, kidney cancer, bladder cancer, melanoma, breast cancer, acute and chronic myelogenous leukemia. The use of these drugs is less toxic than classical chemotherapy, but it can cause gastrointestinal, cardiovascular, respiratory, skin and endocrine complications. Most of the side effects of new cancer therapies are mild and moderate disorders, however some might be severe and life-threatening. Endocrinopathies are one of the more common side effects of these treatments. They can affect many endocrine glands (pituitary, thyroid, parathyroid, adrenal, pancreas) and cause both transient and permanent disorders.

Publisher

Walter de Gruyter GmbH

Subject

Infectious Diseases,Microbiology (medical)

Reference77 articles.

1. Abdulrahman R.M., Verloop H., Hoftijzer H., Verburg E., HovensG.C., Corssmit E.P., Reiners C., Gelderblom H., Pereira A.M.,Kapiteijn E., Romijn J.A., Visser T.J., Smit J.W.: Sorafenib-inducedhypothyroidism is associated with increased type 3 deiodination.J. Clin. Endocrinol. Metab., 2010; 95: 3758–3762

2. Angell T.E.: Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associatedwith improved overall survival. Clin. Thyroidol., 2020; 32: 65–68

3. Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M.,Kageyama K., Imagawa A., Akamizu T.: Management of immunerelatedadverse events in endocrine organs induced by immunecheckpoint inhibitors: clinical guidelines of the Japan EndocrineSociety. Endocr. J., 2019; 66: 581–586

4. Baldazzi V., Tassi R., Lapini A., Lunghi A., Garofoli E., Caruso S.,Carini M., Mazzanti R.: Sunitinib-induced hyperparathyroidism:A possible mechanism to altered bone homeostasis. Cancer, 2012;118: 3165–3172

5. Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S.,Min L., Krop I.E., Tolaney S.M.: Incidence of endocrine dysfunctionfollowing the use of different immune checkpoint inhibitorregimens: A systematic review and meta-analysis. JAMA Oncol.,2018; 4: 173–182

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3